poisar

Stocks · News reference

Artelo Biosciences shares are trading higher after the company announced the filing of a provisional patent application for ART27.13 as a monotherapy and in combination with GLP-1 receptor agonists.

BenzingaBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. BenzingaHenry Khederian

    Artelo Biosciences (ARTL) Stock Surges Wednesday: What's Happening?

    Artelo Biosciences, Inc. (NASDAQ: ARTL) shares are surging Wednesday afternoon after the clinical-stage biopharmaceutical company announced the filing of a new provisional patent application covering its drug candidate ART27.13 for the treatment of obesity.